Double heterozygous pathogenic variants in the BRCA1 and BRCA2 genes in a patient with bilateral metachronous breast cancer

      Abstract

      Double heterozygosity pathogenic variants in BRCA1 and BRCA2 genes are a very rare finding, particularly in non-Ashkenazi individuals. We described the first case of double heterozygosity variants in a non-Ashkenazi Argentinean woman with metachronous bilateral breast cancer. The proband is a 65-year-old female diagnosed with invasive ductal carcinoma in the left breast at 45 years old and invasive carcinoma in the right breast at 65 years old. She underwent a multi-gene panel testing indicating the presence of two concurrent heterozygous germline deleterious variants NM_007300.4(BRCA1):c.4201C>T (p.Gln1401Ter), and NM_000059.3(BRCA2):c.5146_5149del (p.Tyr1716fs). . The patient's son (40 years-old) was found to have the inherited pathogenic variant in BRCA2 gene. There are few reports of double heterozygosity variants in BRCA1 and BRCA2 genes in Latin America. The two pathogenic variants identified in our patient have not been described together so far.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kuchenbaeker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • Phillips K.-.A.
        • Mooij T.M.
        • Roos-Blom M.-.J.
        • et al.
        Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
        JAMA. 2017; 317: 2402-2416https://doi.org/10.1001/jama.2017.7112
        • Leegte B.
        • van der Hout A.H.
        • Deffenbaugh A.M.
        • Bakker M.K.
        • Mulder I.M.
        • ten Berge A.
        • et al.
        Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
        J Med Genet. 2005; 42: e20https://doi.org/10.1136/jmg.2004.027243
        • Vietri M.T.
        • Caliendo G.
        • D´Elia G.
        • Resse M.
        • Casamassimi A.
        • Minucci P.B.
        • et al.
        Five Italian Families with Two Mutations in BRCA Genes.
        Genes (Basel). 2020; 11: 1451https://doi.org/10.3390/genes11121451
        • Dutil J.
        • Golubeva V.A.
        • Pacheco-Torres A.L.
        • Diaz-Zabala H.J.
        • Matta J.L.
        • Monteiro A.N
        The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective.
        Breast Cancer Res Treat. 2015; 154: 441-453https://doi.org/10.1007/s10549-015-3629-3
        • Ossa C.A.
        • Torres D
        Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: state of the Art and Literature Review.
        Oncologist. 2016; 21: 832-839https://doi.org/10.1634/theoncologist.2015-0416
        • Jara L.
        • Morales S.
        • de Mayo T.
        • Gonzalez-Hormazabal P.
        • Carrasco V.
        • Godoy R
        Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
        Biol Res. 2017; 50: 35https://doi.org/10.1186/s40659-017-0139-2
        • Urbina-Jara L.K.
        • Rojas-Martinez A.
        • Martinez-Ledesma E.
        • Aguilar D.
        • Villarreal-Garza C.
        • Ortiz-Lopez R
        Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: opportunities for PARP-Like Inhibitors and Immunotherapy.
        Genes (Basel). 2019; 10: 786https://doi.org/10.3390/genes10100786
        • Solano A.R.
        • Cardoso F.C.
        • Romano V.
        • Perazzo F.
        • Blas C.
        • Recondo G.
        • et al.
        Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: impact on healthcare and clinical practice.
        Oncotarget. 2017; 8: 60487-60495https://doi.org/10.18632/oncotarget.10814
        • Shi T.
        • Wang P.
        • Xie C.
        • Yin S.
        • Shi D.
        • Wei C.
        • et al.
        BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
        Int J Cancer. 2017; 140: 2051-2059https://doi.org/10.1002/ijc.30633
        • Lesueur F.
        • Mebirouk N.
        • Jiao Y.
        • Barjhoux L.
        • Belotti M.
        • Laurent M.
        • et al.
        GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.
        Front Oncol. 2018; 8: 490https://doi.org/10.3389/fonc.2018.00490
        • Beristain E.
        • Ibáñez B.
        • Vergara I.
        • Martínez-Bouzas C.
        • Guerra I.
        • Tejada M.I
        Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.
        J Community Genet. 2010; 1: 91-99https://doi.org/10.1007/s12687-010-0014-0
        • Janavičius R
        Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.
        EPMA J. 2010; 1: 397-412https://doi.org/10.1007/s13167-010-0037-y
        • Gonzalez-Hormazabal P.
        • Gutierrez-Enriquez S.
        • Gaete D.
        • Reyes J.M.
        • Peralta O.
        • Waugh E.
        • et al.
        Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families.
        Breast Cancer Res Treat. 2011; 126: 705-716https://doi.org/10.1007/s10549-010-1170-y
        • Cardoso F.C.
        • Goncalves S.
        • Mele P.G.
        • Liria N.C.
        • Sganga L.
        • Diaz Perez I.
        • et al.
        BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
        Hum. Genomics. 2018; 12: 39https://doi.org/10.1186/s40246-018-0171-5
        • Rebbeck T.R.
        • Mitra N.
        • Wan F.
        • Sinilnikova O.M.
        • Healey S.
        • McGuffog L.
        • et al.
        Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer.
        JAMA. 2015; 313: 1347-1361https://doi.org/10.1001/jama.2014.5985
        • Rebbeck T.R.
        • Friebel T.M.
        • Friedman E.
        • Hamann U.
        • Huo D.
        • Kwong A.
        • et al.
        Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations.
        Hum Mutat. 2018; 39: 593-620https://doi.org/10.1002/humu.23406
        • Ow S.G.W.
        • Ong P.Y.
        • Lee S.C
        Discoveries beyond BRCA1/2: multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
        PLoS ONE. 2019; 14e0213746https://doi.org/10.1371/journal.pone.0213746
        • Gallardo M.
        • Silva A.
        • Rubio L.
        • Alvarez C.
        • Torrealba C.
        • Salinas M.
        • et al.
        Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype–phenotype correlations.
        Breast Cancer Res Treat. 2006; 95: 81-87https://doi.org/10.1007/s10549-005-9047-1
        • Heidemann S.
        • Fischer C.
        • Engel C.
        • Fischer B.
        • Harder L.
        • Schlegelberger B.
        • et al.
        Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
        Breast Cancer Res Treat. 2012; 134: 1229-1239https://doi.org/10.1007/s10549-012-2050-4
        • Smith M.
        • Fawcett S.
        • Sigalas E.
        • Bell R.
        • Devery S.
        • Andrieska N.
        • Winship I.
        Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
        Fam Cancer. 2008; 7: 119-124https://doi.org/10.1007/s10689-007-9154-8
        • Nyberg T.
        • Frost D.
        • Barrowdale D.
        • Evans D.G.
        • Bancroft E.
        • Adlard J.
        • et al.
        Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: a Prospective Cohort Study.
        Eur Urol. 2020; 77: 24-35https://doi.org/10.1016/j.eururo.2019.08.025
        • Patel V.L.
        • Busch E.L.
        • Friebel T.M.
        • Cronin A.
        • Leslie G.
        • McGuffog L.
        • et al.
        Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
        Cancer Res. 2020; 80: 624-638https://doi.org/10.1158/0008-5472.CAN-19-1840
        • Daly M.B.
        • Pal T.
        • Berry M.P.
        • Buys S.S.
        • Dickson P.
        • Domchek S.M.
        • et al.
        NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: breast, Ovarian, and Pancreatic, Version 2.2021.
        J Natl Compr Canc Netw. 2021; 19: 77-102https://doi.org/10.6004/jnccn.2021.0001